Literature DB >> 16624395

Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils.

N Salomé1, J Stemmelin, C Cohen, G Griebel.   

Abstract

There is a growing interest in the potential anxiolytic- and antidepressant-like effects of compounds that target neurokinin receptors. Since the structure and the pharmacology of the human neurokinin receptor resembles that of gerbils, rather than that of mice or rats, we decided to investigate the anxiolytic- and /or antidepressant-like effects of NK1 (SSR240600), NK2 (saredutant) and NK3 (osanetant) receptor antagonists in gerbils. It was found that saredutant (3-10 mg/kg, p.o.) and osanetant (3-10 mg/kg, p.o.) produced anxiolytic-like effects in the gerbil social interaction test. These effects were similar to those obtained with the V1b receptor antagonist SSR149415 (3-10 mg/kg, p.o.), diazepam (1 mg/kg, p.o.) and buspirone (10 mg/kg, p.o.). Fluoxetine and SSR240600 were devoid of effects in this test. In the tonic immobility test in gerbils, saredutant (5-10 mg/kg, i.p.) and osanetant (5-10 mg/kg, i.p.) produced similar effects to those observed with fluoxetine (7.5-15 mg/kg, i.p.), SSR149415 (10-30 mg/kg, p.o.) and buspirone (3 mg/kg, i.p.). Diazepam and SSR240600 were inactive in this paradigm. In conclusion, the present study indicates further that NK2 and NK3 receptor antagonists may have therapeutic potential in the clinical management of anxiety and depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624395     DOI: 10.1016/j.pbb.2006.03.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Characterization of nuclear neurokinin 3 receptor expression in rat brain.

Authors:  C D Sladek; W Stevens; S R Levinson; Z Song; D D Jensen; F W Flynn
Journal:  Neuroscience       Date:  2011-09-08       Impact factor: 3.590

2.  Trafficking of tachykinin neurokinin 3 receptor to nuclei of neurons in the paraventricular nucleus of the hypothalamus following osmotic challenge.

Authors:  D Jensen; Z Zhang; F W Flynn
Journal:  Neuroscience       Date:  2008-05-24       Impact factor: 3.590

Review 3.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

Review 4.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

5.  Activation of tachykinin, neurokinin 3 receptors affects chromatin structure and gene expression by means of histone acetylation.

Authors:  Amit Thakar; Elise Sylar; Francis W Flynn
Journal:  Peptides       Date:  2012-09-15       Impact factor: 3.750

Review 6.  Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?

Authors:  Catherine Belzung
Journal:  Neuropsychopharmacology       Date:  2013-12-18       Impact factor: 7.853

Review 7.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

8.  Tacr3 in the lateral habenula differentially regulates orofacial allodynia and anxiety-like behaviors in a mouse model of trigeminal neuralgia.

Authors:  Wen-Qiang Cui; Wen-Wen Zhang; Teng Chen; Qian Li; Fei Xu; Qi-Liang Mao-Ying; Wen-Li Mi; Yan-Qing Wang; Yu-Xia Chu
Journal:  Acta Neuropathol Commun       Date:  2020-04-07       Impact factor: 7.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.